Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Q1 Revenues up 15 Percent

NEW YORK — Bruker on Thursday reported a 15 percent year-over-year increase in first quarter revenues with gains across all of its business segments.

For the three-month period ended March 31, Bruker's revenues climbed to $685.3 million from $595.0 million the year before. Analysts had, on average, been expecting revenues of about $639.8 million.

Growth from acquisitions was up around 2 percent and offset by a negative effect from foreign currency translation of 4.5 percent.

Bruker's CALID unit, which includes its life sciences and mass spectrometry business, posted a 16 percent jump in revenues for the quarter to $236.7 million from $203.2 million a year earlier. Bruker BioSpin revenues were up 14 percent in the first quarter to $180.3 million from $157.8 million, while Bruker Nano's revenues rose 17 percent to $209.6 million from $178.5 million. Bruker Energy & Supercon Technologies (BEST) revenues edged up 4 percent to $62.2 million from $59.7 million.

Bruker reported a first quarter net profit of $76.5 million, or $.52 per share, compared with a year-ago profit of $61.6 million, or $.41 per share. Non-GAAP earnings per share in Q1 2023 were $.64, topping the consensus Wall Street estimate of $.55 per share.

The Billerica, Massachusetts-based company's R&D costs in the quarter increased 22 percent to $69.0 million from $56.6 million, while SG&A spending rose nearly 12 percent to $162.7 million from $145.7 million.

Bruker ended the quarter with cash, cash equivalents, and restricted cash of $601.4 million.

Looking ahead, Bruker said that it is raising its revenue guidance for full-year 2023 to between $2.83 billion and $2.88 billion compared to a previous outlook of $2.81 billion to $2.86 billion. The raised guidance implies 12 percent to 14 percent year-over-year reported revenue growth including organic revenue growth of 9 percent to 11 percent.

The company now expects non-GAAP earnings for 2023 of between $2.55 and $2.60 per share, up from prior guidance of $2.52 to $2.57 per share.

During early morning trading on the Nasdaq, shares of Bruker were up $3.53 to $83.76.

The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.